Department of Nephrology, Aalborg University Hospital
Aalborg, 9000, Denmark
NCT Number: NCT06526702
This randomized, crossover study aims to investigate the intradialytic kinetics of selected cardiac biomarkers in patients with end-stage renal disease treated with dialysis. The cardiac biomarkers of interest include high-sensitivity cardiac troponin I, high-sensitivity cardiac troponin T, brain natriuretic peptide, and a novel cardiac biomarker named secretoneurin.
In 24 patients treated with maintenance hemodialysis, the study will compare high-flux hemodialysis (HD) with post-dilution hemodiafiltration (HDF) to investigate:
* Baseline concentrations and week-to-week plasma variations of the cardiac biomarkers. * Changes in the plasma concentrations of the cardiac biomarkers during high-flux HD and post-dilution HDF. * Dialyzer clearance of the cardiac biomarkers in high-flux HD and post-dilution HDF. * Adherence of the cardiac biomarkers to the dialyzer membrane. * Concentrations of the cardiac biomarkers 30 minutes post-dialysis to investigate a potential rebound effect.
Additionally, a sub-study of 24 patients treated with peritoneal dialysis will investigate the baseline concentrations and week-to-week plasma variations of the same cardiac biomarkers.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Aalborg, 9000, Denmark
Patients treated with maintenance hemodialysis:
Single-center, randomized, crossover study with 24 participants. The study will investigate the effect of high-flux HD (using the FX CorDiax 100 dialyzer) and post-dilution HDF (using the FX CorDiax 1000 dialyzer) on the intradialytic kinetics of selected cardiac biomarkers. The study will not be blinded, but the order of the interventions will be randomized. The two dialysis sessions will be conducted on the same weekday. Between the two interventions, the patient will have a wash-out period of 1-3 weeks with standard dialysis treatment.
On both trial days, the following dialysis settings will be the same for each individual patient:
On both trial days, different baseline characteristics will be gathered, including demographic data, clinical data, dialysis characteristics, and routine blood samples. Blood samples, for the analysis of the selected cardiac biomarkers, will be collected:
Sub-study of patients treated with peritoneal dialysis:
In a sub-study, 24 patients treated with peritoneal dialysis, will be included for one or two venous blood samples (with a minimum of 1 week between) to determine the baseline concentration and week-to-week variation of the cardiac biomarkers of interest. On both trial days, different baseline characteristics will be gathered, including demographic data, clinical data, dialysis characteristics, and routine blood samples.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
FX CorDiax 100 dialyzer
FX CorDiax 1000 dialyzer
Time frame: Before the start of a dialysis session; after 10, 30, 60, 120, 180, and 240 minutes of dialysis; and 5-30 min. after dialysis cessation.
Changes in the selected cardiac biomarkers from baseline, to after 10, 30, 60, 120, 180, and 240 minutes of dialysis, and 5-30 min. after dialysis cessation in both high-flux hemodialysis and post-dilution hemodiafiltration. The two dialysis modalities will be compared.
Time frame: After 120 minutes of dialysis.
Dialyzer clearance, calculated by dialysate and blood after 120 minutes of dialysis, of the cardiac biomarkers in high-flux hemodialysis and post-dilution hemodiafiltation. The two dialysis modalities will be compared.
Time frame: After 120 minutes of dialysis.
Adherence of the cardiac biomarkers to the dialyzer membrane after 120 minutes of dialysis in high-flux hemodialysis and post-dilution hemodiafiltation. The two dialysis modalities will be compared.
Time frame: Baseline.
Concentrations of the cardiac biomarkers in patients treated with hemodialysis and peritoneal dialysis.
Time frame: At baseline on two different days with a minimum of 1 week between.
Changes in plasma concentrations of the cardiac biomarkers at baseline on both intervention days.
Time frame: 5-30 minutes after dialysis cessation.
Concentrations of the cardiac biomarkers 5-30 minutes post-dialysis to investigate a potential rebound effect.
Aalborg University Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05159999
End Stage Renal Disease on Dialysis
San Francisco, California, United States
View Trial DetailsNCT07086430
End Stage Renal Disease on Dialysis, Female Urogenital Diseases
View Trial DetailsNCT06581393
Chronic Disease, Disease Attributes
Ontario, California, United States
View Trial DetailsNCT05540457
Chronic Disease, Dialysis Hypotension
New York, United States
View Trial Details